FentaGone creates needle that tests overdose risk
Edmonton startup FentaGone has developed a syringe that detects fentanyl and allows a user to test their drugs wherever they take them to avoid an overdose.
"What we've seen is a lot of changes in regards to harm reduction across the province and across the city, whether that comes to safe consumption sites opening, closing, moving — there's been a lot of unknowns in this sphere," FentaGone co-founder and CEO Simran Dhillon told Taproot. "What we see as a result of that, too, is overdose rates are increasing every single year, and it's getting exceptionally worse. And B.C., Alberta, and Ontario are the hardest hit."
FentaGone was a participant in Cohort 4 of the TELUS Community Safety and Wellness Accelerator, an Alberta-focused business accelerator focusing on entrepreneurial solutions to social and safety challenges in communities. The cohort closed and demonstrations took place on Dec. 6. The program introduces participants to community agencies and government partners like the Edmonton Police Service.
In all of 2022, emergency teams in Edmonton responded to 3,503 opioid-related events. By just the end of October 2023 (November and December data are not yet available) emergency teams have responded to 4,450 such events, according to Alberta's substance use surveillance data. For further context, Canada's Health InfoBase reports that fentanyl was involved in 81% of "all accidental apparent opioid toxicity deaths" from January to March of 2023.
While mass spectrometry machines at supervised consumption sites and test strips both test for fentanyl, each has challenges. The strips have reliability and context challenges, while the machines are relatively inaccessible due to the time and materials they require, as well as the user needing to go to the few locations where they are located.
FentaGone has worked to eliminate these significant barriers by creating a tool called FentaGone that is within the very syringe a user can employ to inject a drug. This allows a user to test wherever they intend to use a drug.
"Nothing changes in the ritual behaviour: there's no additional steps, no additional education, and we have embedded a unique functional detection technology into the plastic of the syringe and as it binds to fentanyl, it will change colour," Dhillon said. If a lethal fentanyl concentration is present, the substance within will become intensely red. If fentanyl is present but not in a lethal concentration, it will be a muted yellow, Dhillon said.
This provides more context to users than test strips, which indicate only whether fentanyl is present or not.
Test strips give you a response that isn't really assessing your risk of an overdose, Dhillon said. "It just assesses if fentanyl is present or not and fentanyl is very concentrated in the drug sphere at the moment. So, knowing if there's fentanyl present or not isn't as valuable as knowing how much fentanyl is potentially present."